Chronic inflammation in Alzheimer’s disease offers therapeutic opportunities

References

• Eikelenboom P, Hack CE, Rozemuller JM,Stam PC. Complement activation in amyloid plaques in Alzheimer's dementia. Vizrhows Azrh. Cel I Farhat. 56,259–262 (1989).
   Google Scholar
• Ishii T, Haga S. Immuno-electron- microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol Oerl) 63,296–300 (1984).
   PubMed Web of Science ®Google Scholar
• •One of the first papers to report an inflammatory mediator in AD brain.
   Google Scholar
• McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can. J. Neural. Sc]. 16, 516–527 (1989).
   PubMed Web of Science ®Google Scholar
• Webster S, Lue LF, Brachova L etal Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobial Aging18, 415–421 (1997).
   PubMed Web of Science ®Google Scholar
• •This paper laid to rest the controversy as to the occurrence of the membrane attack complex in AD brain.
   Google Scholar
• Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Blain Res. 645,78–84 (1994).
   Google Scholar
• McGeer PL, McGeer EG. Autotoxicity and Alzheimer's disease. Arch. Neural. 57, 789–790 (2000).
   PubMedGoogle Scholar
• Jiang H, Robey F, Gewurz H. Localization of sites through which C-reactive protein binds to and activates complement to residues 14–26 and 76–92 of the human Clq A chain. I Exp. Med. 175, 1373–1379 (1992).
   Google Scholar
• •This demonstrated that the mechanism of activation of the complement cascade by molecules, such as C-reactive protein involves different binding to Clq than does the activation by antibodies.
   Google Scholar
• Akiyama H, Yamada T, Kawamata T, McGeer PL. Association of amyloid P component with complement proteins in neurologically diseased tissue. Brain Res. 548, 349–352 (1991).
   PubMed Web of Science ®Google Scholar
• Hicks PS, Saunero-Nazia L, Ducios TW, Mold C. Serum amyloid P component binds to histones and activates the classical complement pathway. j Immuno1.149, 3689–3694 (1992).
   Google Scholar
• Rogers J, Webster S, Schultz J etal Complement activation by 13-amyloid in Alzheimer's disease. Proc. Natl Acad. Sc]. USA 89, 10016–10020 (1992).
   Google Scholar
• •This was the first demonstration that this key component of the senile plaques of AD could activate the complement cascade.
   Google Scholar
• Watson MD, Roher AE, Kim KS, Spiegel K, Emmerling MR. Complement interactions with amyloid 1–42: a nidus for inflammation in AD brains. Amyloicl 4, 147–156 (1997).
   Google Scholar
• Metchnikoff E. Lecons sur la pathologie comparée de l'inflammation, Masson, Paris, (1892).
   Google Scholar
• Del Rio Hortega P. El `tercer elemento' de los centros nerviosos. Poder fagocitario y movilidad de la microglia. Bal. Soc. Esp. Biol. Ana. ix, 154–166 (1919).
   Google Scholar
• •The first description of microglia in brain.
   Google Scholar
• Akiyama H, McGeer PL. Brain microglia constitutively express 132 integrins. Neuroimmunal 30, 81–93 (1990).
   PubMed Web of Science ®Google Scholar
• Rozemuller JM, Eikelenboom P, Pals ST, Stam PC. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett.101,288-292 (1989).
   Google Scholar
• McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79, 195–200 (1987).
   PubMed Web of Science ®Google Scholar
• •The first published report of activated microglia in affected regions of AD brain.
   Google Scholar
• Rogers J, Luber-Narod J, Sturen CD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobial Aging9, 339–349 (1988).
   PubMed Web of Science ®Google Scholar
• Giulian D, Haverkamp LJ, Yu JH etal Specific domains of 13-amyloid from Alzheimer plaque elicit neurone killing in human microglia. j Neurosci. 16, 6021 — 6037 (1996).
   Web of Science ®Google Scholar
• Klegeris A, McGeer PL. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J. Leukocyte Bio1.67, 127–133 (2000).
   Google Scholar
• Schenk D, Barbour R, Dunn W etal Immunization with amyloid-13 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• •This was a prize-winning report that showed that immunization with 1-amyloid decreased amyloid deposits in transgenic mouse brain, a finding that has led to a clinical trial of such immunization in humans with AD.
   Google Scholar
• Kuo Y-M, Kokjohn TA, Beach TG et al Comparative analysis of A13 chemical structure and amyloid plaque morphology of transgenic mice and Alzheimer's disease brains. Proc. Natl Acad. Sc]. USA (In Press)
   Google Scholar
• Wood JA, Wood PL, Ryan R etal Cytokine indices in Alzheimer's temporal cortex: no change in mature IL I or IL-1RA but increases in the associated acute phase proteins IL-6, a 2-macroglobulin and C-reactive protein. Brain Res. 629, 245–252 (1993).
   PubMed Web of Science ®Google Scholar
• Cacebelos R, Alvarez XA, Fernandez-Novoa I etal Brain interleukin-1 I in Alzheimer's disease and vascular dementia. Meth. Find. Exp. Clin. Pharmacol 16, 141–145 (1994).
   Google Scholar
• Dickson DW, Lee SC, Mattiace LA, Yen SHC, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Gila 7, 75–83 (1993).
   Google Scholar
• Griffin WST, Stanley LC, Ling C et al Brain interleukin-1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer's disease. Proc. Natl Acad. Sc]. USA 86, 7611–7615 (1989).
   Google Scholar
• Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains, j Neurosci. Res. 40, 478–493 (1995).
   Google Scholar
• Yamabe T, Dhir G, Cowan EP eta]. Cytokine-gene expression in measles-infected adult human glial cells. J. Neuroimmunal 49, 171–179 (1994).
   Google Scholar
• Sharif SF, Hariri RJ, Chang VA, Bane PS, Wang RS, Ghajar JB. Human astrocyte production of tumour necrosis factor-a, interleukin-1 I and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neural. Res. 15, 109–112 (1993).
   Google Scholar
• Lieberman AP, Pitha PM, Shin HS, Shin ML. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl Acad. Sci. USA 86, 6348–6352 (1989).
   PubMed Web of Science ®Google Scholar
• Abraham CR, Shirahama T, Potter H. al- Antichymotrypsin is associated solely with amyloid deposits containing the 13-protein. Amyloid and cell localization of al-antichymotrypsin. Neurobial Agitg 11, 123–129 (1990).
   Google Scholar
• Bauer J, Strauss S, Schreiter-Gasser U eta]. Interleukin-6 and a2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortex. FEBS Lett. 285, 111–114 (1991).
   Google Scholar
• Blacker D, Wilcox MA, Laird NM etal a- 2 -macroglobulin is genetically associated with Alzheimer's disease. Nature Genetics 19, 357–360 (1998).
   PubMed Web of Science ®Google Scholar
• Collins JS, Perry RT, Watson B Jr eta]. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer's disease: The NIMH Alzheimer's disease genetics initiative. Am. J. Med. Genet. 96, 823–830 (2000).
   Google Scholar
• Du Y, Dodel RC, Eastwood BJ et al Association of an interleukin-1 a polymorphism with Alzheimer's disease. Neurology55, 480–483 (2000).
   PubMed Web of Science ®Google Scholar
• Grimaldi LME, Casadei CM, Ferri C et al Association of early-onset Alzheimer's disease with an interleukin- la gene polymorphism. Ann. Neural. 47, 361–365 (2000).
   PubMed Web of Science ®Google Scholar
• Kamboh MI, Aston CE, Ferrell RE, Dekosky ST Genetic effect of a- 1-antichymotrypsin on the risk of Alzheimer's disease. Genomics 40, 382–384 (1997).
   PubMed Web of Science ®Google Scholar
• Licastro F, Pedrini S, Bonafe M eta]. Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affect IL-6 plasma levels. Neurobial Aging-21(1S), S38 (2000).
   Google Scholar
• Licastro F, Pedrini S, Ferri C eta]. Gene polymorphism affecting al-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann. Neural. 48, 388–391 (2000).
   Google Scholar
• Nicoll JAR, Mrak RE, Graham D etal Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neural. 47, 365–368 (2000).
   Google Scholar
• Papassotiropoulos A, Bagli M, Jessen F etal A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neural. 45, 666–668 (1999).
   Google Scholar
• •An initial report linking a polymorphism in an inflammatory cytokine with the risk of AD.
   Google Scholar
• Rebeck GW. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci. Lett. 293, 75–77 (2000).
   Google Scholar
• McCusker SM. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor A and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357, 436–439 (2001).
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Saunders A, Schmechel D etal Apolipoprotein E: high avidity binding to 13-amyloid and increased frequency of Type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl Acad. Sci USA 90, 1977-1981 (1993).
   Google Scholar
• •This paper identified a polymorphism in Apo E as an important risk factor for late-onset AD.
   Google Scholar
• McGeer PL, McGeer EG. Polymorphisms in inflammatory genes enhance the risk of Alzheimer's disease. Arch. Neural. (In Press).
   Google Scholar
• Kalaria RN, Grahovac I. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res. 516, 349–353 (1990).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887, 80–89 (2000).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Upregulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol 154, 927–936 (1999).
   PubMed Web of Science ®Google Scholar
• •One of the first attempts to use quantitative biochemical measures to identify the intensity of the inflammatory reaction in AD brain.
   Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Athol 158, 1039–1051 (2001).
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ. Res. 83, 860–869 (1998).
   PubMed Web of Science ®Google Scholar
• Arnau JM, Agusti A. Is aspirin underused in myocardial infarction? Pharmacoeconomics 12, 524–532 (1997).
   PubMed Web of Science ®Google Scholar
• Bath PMW. The medical management of stroke. hit/f Clin. Prac. 51, 504–510 (1997).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology47, 425–432 (1996).
   Google Scholar
• •This meta-analysis of published epidemiological studies emphasized the probable importance of inflammation in the progression of AD.
   Google Scholar
• Stewart VVF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Aiumlogy48, 626–632 (1997).
   Google Scholar
• Veld BAT, Ruitenberg A, Launer LJ, Hofman A, Breteler MMB, Stricker BHC. Duration of non-steroidal anti-inflammatory drug use and risk of Alzheimer's disease. The Rotterdam study. Neurobiol Aging 21 (1S), S204 (2000).
   Google Scholar
• Rogers J, Kirby LC, Hempelman SR eta]. Clinical trial of indomethacin in Alzheimer's disease. Neurology43,1609–1611 (1993).
   Google Scholar
• •This was the first report of a controlled clinical trial of an anti-inflammatory agent in the treatment of AD.
   Google Scholar
• Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease. Neurology53, 197–201 (1999).
   Google Scholar
• Sainali SM, Ingram DM, Talwaker S et al Results of a double-blind, placebo-controlled study of Celebrid for the progression of Alzheimer's disease. 6th International Stockholm-Springfield Symposium of Advances in Alzheimer Therapy, (2000) .
   Google Scholar
• Ying SC, Gewurz AT Jiang H, Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway vis residues 14-26 and 76-92 of the A chain collagen-like region of Clq. hrimunol 150, 169–176 (1993).
   Google Scholar
• Webster S, Bonnell B, Rogers J. Charge- based binding of complement component Clq to the Alzheimer amyloid I3-peptide. Am. Patna 150, 1531–1536 (1997).
   Google Scholar
• Wallace JL, Pittman Qj, Cirino G. Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. Agents Actions 46(Suppl.), 121–129 (1995).
   Google Scholar
• McGeer PL, Harada N, Kimura H, McGeer EG, Schulzer M, Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 3, 146–149 (1992).
   Google Scholar